Quantcast
Home > Quotes > EPZM
EPZM

Epizyme, Inc. Common Stock (EPZM) Quote & Summary Data

$7.91
*  
0.40
5.33%
Get EPZM Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading EPZM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
21
Today's High / Low
$ 8.265 / $ 7.50
Share Volume
749,025
50 Day Avg. Daily Volume
651,057
Previous Close
$ 7.51
52 Week High / Low
$ 21.40 / $ 7.21
Market Cap
626,219,299
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.97
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
3.17

Intraday Chart

Shares Traded

Share Volume:
749,025
50 Day Avg. Daily Volume:
651,057

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.97

Trading Range

The current last sale of $7.91 is 9.71% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.265 $ 21.40
 Low: $ 7.50 $ 7.21

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. By focusing on the genetic drivers of disease, our science seeks to match targeted medicines with the patients who need them. We are broadly developing our lead product candidate, tazemetostat, an oral, first-in-class selective inhibitor of the EZH2 histone methyltransferase, or HMT, in a range of cancer types and settings, and developing the lead development candidate in our novel G9a program, EZM8266, for the treatment of sickle cell disease, or SCD. We have taken a "pipeline in a product" approach to developing tazemetostat with a broad clinical development program through company-sponsored studies and collaborations that are evaluating tazemetostat as both a monotherapy and combination treatment in both hematological malignancies and solid tumors.  ... More ...  


Risk Grade

Where does EPZM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.50
Open Date:
Nov. 16, 2018
Close Price:
$ 7.51
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x